newsfilter.io

Medical Distribution — industry outlook

  • Period: 2026-10-19 to 2026-11-09
  • Events: 2
  • Generated: 2026-11-09T07:30:00.003Z

Elevated EPS Guidance and Growth Trajectory

MCK raised Fiscal 2027 Adjusted EPS guidance to $45.60–$46.40, implying 17–19% growth ex-divestiture gains, while CAH lifted FY27 Non-GAAP EPS to $12.80–$13.00, representing 17–19% growth ex-tariff refund adjustments. Both companies anticipate revenue growth for their core pharmaceutical or pharma segments, with MCK expecting 6–10% total revenue growth and a 5–9% growth in North American Pharmaceutical, whereas CAH maintains unchanged revenue guidance of 3–5% for its Pharma segment. MCK projects operating profit growth of 12–16% overall and 14–18% for North American Pharmaceutical, while CAH raised its Pharma segment profit growth outlook to 10–12% and expects 18–22% profit growth in its Oncology & Multi-Specialty segment. CAH notes a specific cadence where earnings growth is expected to moderate in Q2–Q3 before strengthening in Q4, whereas MCK anticipates a higher effective tax rate in Q3 compared to Q4 due to discrete timing.

Acceleration in Specialty and Biologics Demand

Specialty and complex care segments are driving outperformance across both entities, with MCK projecting 20–24% revenue growth and 18–22% operating profit growth in Oncology & Multi-Specialty. GLP-1 medication demand remains a primary growth vector; MCK reported $1.6B in Q2 GLP-1 distribution revenue (up 26% YoY) and attributes growth in its Prescription Technology Solutions segment to related support services, while CAH noted GLP-1s contributed approximately 500 basis points to Q1 growth despite offsetting IRA WAC reductions of roughly 400 basis points. MCK highlights significant growth opportunities in precision medicine, anticipating its Precision Medicine Group acquisition will accrete $0.10–$0.20 to Fiscal 2027 EPS and up to $1.60–$1.80 by Year 3. CAH is similarly focused on complex innovation, with its Specialty business growing 18% in Q1 and expecting to double therapies supported by its Synexis Patient Hub by FY28.

Strategic M&A and Integration Roadmaps

Both distributors are actively executing on consolidation strategies to enhance market access and clinical capabilities. MCK closed its ~$2.25B acquisition of Precision Medicine Group and signed a definitive agreement to invest ~$1.4B for a 49% minority interest in Option Care Health, expected to close in H1 calendar year 2027. CAH is integrating its Solaris and Strive acquisitions, with Solaris impacting the full year in Q2 and Strive expected to accelerate at-home solutions in H2 FY27. MCK's segment outlook for Oncology & Multi-Specialty includes an expanded footprint via Spectrum Vision Partners (150+ providers), while CAH targets the deployment of AI route optimization to its full network of 130 radio pharmacies by the end of FY27 and the opening of a new St. Louis 3PL facility by the end of calendar year 2027.

Regulatory Volatility and Macro Cost Headwinds

A divergence exists regarding the impact of specific regulatory and commodity cost factors. MCK reports no anticipated material financial impact from the 340B program and expects to maintain margin integrity as a slate of biosimilars launches in the next 12 months. In contrast, CAH anticipates reimbursement changes may shift volume to them as providers navigate affordability, but warns that ongoing Iran conflict-driven petroleum costs could push its GMPD segment profit to the low end of its $200–$220 million guidance. Both companies cite IRA WAC reductions as a recurring revenue headwind, with CAH noting a ~400 bps YoY drag and MCK identifying WAC decreases as impacting revenue lines in its North American Pharmaceutical segment, though less so on operating profit. CAH further notes that FX and distribution headwinds are present in GMPD, while MCK expects to face variability in Medical-Surgical Solutions due to annual illness season severity.

Capital Allocation and Shareholder Returns

Capital deployment priorities emphasize disciplined growth alongside aggressive share repurchase programs. MCK expects Fiscal 2027 Free Cash Flow of $4.5–$4.9 billion and has committed to approximately $5 billion in share repurchases, having already purchased $3.4 billion in the first half at an average price of $81.80 per share. CAH projects adjusted free cash flow of $3.5–$4.0 billion for FY27, supported by $5.3B in ending cash, and maintains an annual $1 billion buyback commitment (with 50% utilized) alongside a ~$125M annual dividend. Both companies project an effective tax rate in the 18–19.5% range for FY27, with MCK citing interest expenses in the high end of $380–$420 million and CAH forecasting interest and other expenses of $240–$290 million.